Mikkel W. Pedersen

Mikkel joined Nykode Therapeutics in 2021. He has long experience in drug discovery and development within the areas of oncology, immuno-oncology and infectious diseases. His previous roles include Head of Biologics Drug Design at Servier and CSO of Symphogen, where he has also held the positions VP of Antibody Discovery and Research and Director of Cancer Biology and Immunology. Before that, Mikkel was leader of the receptor tyrosine kinase group at the Department of Radiation Biology at the Copenhagen University Hospital. Mikkel holds a Ph.D. from the University of Copenhagen and has authored over 40 peer-reviewed publications.